Last reviewed 2026-04-20 · How we verify

Antiseptic Solution

Antiseptic Solution, marketed by Northern State Medical University, holds a position in the antiseptic market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and regulatory approval. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Effect of Antiseptic Irrigations With 0.05% Chlorhexidine Gluconate (Irrisept) Versus Normal Saline on Fasciocutaneous Flap-Based Closure of Pilonidal Disease (NA)
• CLinical Evaluation of ANtiseptic Skin Preparation in Revision Total Joint Arthroplasty of the Hip and Knee (NA)
• Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE) (PHASE3)
• Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation (PHASE3)
• Stellate Ganglion Blockade for Refractory Chronic Migraine (NA)
• Effects of Squeezing Ball and Using Adhesive Remover on Pain and Fear in Children Aged 6-9 Years During the Removal of Peripheral Intravenous Cannula (NA)
• Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radiotherapy (CONCERTO) (PHASE2)
• Influence of Antiseptic Washes on Wound Healing Complications After THA (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.